[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK3272342T3 - Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse - Google Patents

Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse Download PDF

Info

Publication number
DK3272342T3
DK3272342T3 DK17187023.1T DK17187023T DK3272342T3 DK 3272342 T3 DK3272342 T3 DK 3272342T3 DK 17187023 T DK17187023 T DK 17187023T DK 3272342 T3 DK3272342 T3 DK 3272342T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
attention deficit
deficit disorder
treating attention
Prior art date
Application number
DK17187023.1T
Other languages
English (en)
Inventor
Feng Zhang
David Lickrish
Original Assignee
Ironshore Pharmaceuticals & Dev Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironshore Pharmaceuticals & Dev Inc filed Critical Ironshore Pharmaceuticals & Dev Inc
Application granted granted Critical
Publication of DK3272342T3 publication Critical patent/DK3272342T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17187023.1T 2011-03-23 2012-03-23 Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse DK3272342T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161466684P 2011-03-23 2011-03-23
US201161561763P 2011-11-18 2011-11-18
US201261591129P 2012-01-26 2012-01-26
EP12760068.2A EP2688557B1 (en) 2011-03-23 2012-03-23 Methods and compositions for treatment of attention deficit disorder

Publications (1)

Publication Number Publication Date
DK3272342T3 true DK3272342T3 (da) 2021-06-07

Family

ID=46879766

Family Applications (3)

Application Number Title Priority Date Filing Date
DK17187023.1T DK3272342T3 (da) 2011-03-23 2012-03-23 Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse
DK12760068.2T DK2688557T3 (da) 2011-03-23 2012-03-23 Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
DK21174219.2T DK4011364T3 (da) 2011-03-23 2012-03-23 Fremgangsmåder og sammensætninger til behandling af ADD (Attention Deficit Disorder)

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK12760068.2T DK2688557T3 (da) 2011-03-23 2012-03-23 Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
DK21174219.2T DK4011364T3 (da) 2011-03-23 2012-03-23 Fremgangsmåder og sammensætninger til behandling af ADD (Attention Deficit Disorder)

Country Status (15)

Country Link
US (1) US9028868B2 (da)
EP (4) EP4011364B1 (da)
JP (7) JP6043785B2 (da)
KR (2) KR20160135373A (da)
CN (2) CN110151731A (da)
AU (3) AU2012230733B2 (da)
BR (1) BR112013024401B1 (da)
CA (1) CA2830788C (da)
DK (3) DK3272342T3 (da)
ES (3) ES2883589T3 (da)
MX (3) MX357551B (da)
PT (3) PT3272342T (da)
SG (2) SG10201901167SA (da)
WO (1) WO2012129551A1 (da)
ZA (1) ZA201307649B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498447B2 (en) * 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) * 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) * 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) * 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10905652B2 (en) * 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
GB201319791D0 (en) * 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
SG11201708393UA (en) * 2015-05-04 2017-11-29 Confluence Pharmaceuticals Llc Sprinkle formulations of acamprosate
US20190008787A1 (en) * 2015-07-17 2019-01-10 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
US10383825B2 (en) 2015-08-13 2019-08-20 Temple University—Of the Commonwealth System of Higher Education Calcium alginate dosage formulations, and methods of making and using thereof
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
US20190111001A1 (en) * 2016-03-30 2019-04-18 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
KR20190013737A (ko) * 2016-05-26 2019-02-11 오비드 테라퓨틱스 인크. 피프라드롤을 이용한 행동 증후군들의 치료 방법들
JP7258561B2 (ja) * 2016-07-06 2023-04-17 オリエント ファーマ シーオー．，エルティーディー． 薬物組成物、バリヤー層及び薬物層を有している経口投与形態
US9931303B1 (en) * 2017-02-06 2018-04-03 Alcobra Ltd. Abuse deterrent formulations of amphetamine
US20180256515A1 (en) * 2017-03-10 2018-09-13 Adare Pharmaceuticals, Inc. Oral amphetamine composition
WO2018199282A1 (ja) * 2017-04-28 2018-11-01 アステラス製薬株式会社 エンザルタミドを含有する経口投与用医薬組成物
CA3062834A1 (en) 2017-05-17 2018-11-22 Confluence Pharmaceuticals, Llc Formulations of homotaurines and salts thereof
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
CN108653243B (zh) * 2018-03-30 2019-03-22 江苏南农高科动物药业有限公司 一种缓释替米考星微囊粉的制备方法
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3914248A4 (en) * 2019-01-25 2022-10-12 Ironshore Pharmaceuticals & Development, Inc. METHYLPHENIDATE COMPOSITIONS FOR THE TREATMENT OF ATTENTION DEFICIT AND HYPERACTIVITY DISORDER

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8322007D0 (en) 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4904476A (en) 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
CA2047738C (en) 1989-02-16 2000-02-15 Marion Eileen Mcneill Dispensing device
JP2558396B2 (ja) 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
IL109460A (en) 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
JP2916978B2 (ja) 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
US5658590A (en) 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
IT1276689B1 (it) 1995-06-09 1997-11-03 Applied Pharma Res Forma farmaceutica solida ad uso orale
GB9514451D0 (en) 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US6355656B1 (en) 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5922736A (en) 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
MX9805870A (da) 1996-01-22 1999-01-31
CA2243534C (en) 1996-02-02 2003-08-26 Medeva Europe Limited Process for the preparation of d-threo-(r,r)-methylphenidate and recycling of undesired enantiomers by epimerisation
EP0885191B1 (en) 1996-03-08 2002-01-23 Medeva Europe Limited Resolution of threo-methylphenidate
GB9606417D0 (en) 1996-03-27 1996-06-05 Chiroscience Ltd Asymmetric cyclisation
DE69735581T2 (de) 1996-09-30 2007-01-25 Alza Corp., Palo Alto Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
CN1182839C (zh) 1996-11-25 2005-01-05 阿尔萨公司 递增剂量的剂型
EP1782798A3 (en) 1996-11-25 2008-05-21 Alza Corporation Ascending-dose dosage form
JP2001506621A (ja) 1996-12-13 2001-05-22 メデバ・ユアラプ・リミテッド エナンチオマー濃縮されたトレオ−メチルフェニデートの調製法
GB9700912D0 (en) 1997-01-17 1997-03-05 Chiroscience Ltd Resolution
US6210705B1 (en) 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
EP1117384A1 (en) * 1998-10-01 2001-07-25 Elan Pharma International Limited Controlled release nanoparticulate compositions
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
AU770645B2 (en) 1998-11-02 2004-02-26 Alkermes Pharma Ireland Limited Multiparticulate modified release composition
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6384020B1 (en) 1999-07-14 2002-05-07 Shire Laboratories, Inc. Rapid immediate release oral dosage form
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
GB9918735D0 (en) * 1999-08-09 1999-10-13 Straken Limited Transdermal patches
US6898455B2 (en) 1999-10-29 2005-05-24 The Mclean Hospital Corporation Method for providing optimal drug dosage
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US6569456B2 (en) 2000-01-13 2003-05-27 Osmotica Corp. Osmotic device containing diltiazem and an ACE inhibitor or diuretic
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6520921B1 (en) 2000-06-20 2003-02-18 Eastman Kodak Company Method for determining attention deficit hyperactivity disorder (ADHD) medication dosage and for monitoring the effects of (ADHD) medication
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US20030232890A1 (en) 2000-11-01 2003-12-18 Sention, Inc. Methods for treating an impairment in memory consolidation
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20040137062A1 (en) 2001-05-25 2004-07-15 Sham Chopra Chronotherapy tablet and methods related thereto
IL159715A0 (en) * 2001-07-10 2004-06-20 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US6811794B2 (en) 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7105486B2 (en) 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US6726624B2 (en) 2002-03-06 2004-04-27 The Mclean Hospital Corporation Method and apparatus for determining attention deficit hyperactivity disorder (adhd) medication dosage and for monitoring the effects of adhd medication on people who have adhd using complementary tests
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
AU2003270349A1 (en) 2002-09-09 2004-03-29 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
EP1589951B1 (en) 2003-01-03 2017-08-09 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
ES2380622T5 (es) 2003-05-29 2018-05-30 Shire Llc Compuestos de anfetamina resistentes al abuso
US20050031688A1 (en) 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
ATE388146T1 (de) 2004-01-29 2008-03-15 Pfizer 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
ES2261006B1 (es) * 2004-06-10 2007-11-01 Laboratorios Rubio, S.A. Pellet multicapa de liberacion controlada de metilfenidato.
US20070036843A1 (en) 2005-01-28 2007-02-15 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
FR2892937B1 (fr) * 2005-11-10 2013-04-05 Flamel Tech Sa Forme pharmaceutique orale microparticulaire anti-mesusage
ES2626632T3 (es) 2006-05-09 2017-07-25 Mallinckrodt Llc Formas de dosificación sólidas de liberación modificada de orden cero
WO2007133203A1 (en) * 2006-05-12 2007-11-22 Shire Llc Controlled dose drug delivery system
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
FR2901478B1 (fr) * 2006-05-24 2015-06-05 Flamel Tech Sa Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
CN1985810A (zh) * 2006-07-28 2007-06-27 中国人民解放军第二军医大学 盐酸哌甲酯缓控释胶囊及其制备方法
KR100888131B1 (ko) 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
WO2008054123A1 (en) 2006-10-30 2008-05-08 Hanall Pharmaceutical Company, Ltd. Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors
CN103120653B (zh) 2007-04-04 2015-09-30 希格默伊德药业有限公司 一种口服药物组合物
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
MX2010008138A (es) * 2008-01-25 2010-08-10 Gruenenthal Gmbh Forma de dosis farmaceutica.
CA2627198A1 (en) 2008-03-27 2009-09-27 Pharmascience Inc. Methylphenidate extended release therapeutic drug delivery system
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse

Also Published As

Publication number Publication date
PT4011364T (pt) 2024-02-07
ES2973539T3 (es) 2024-06-20
JP2014508812A (ja) 2014-04-10
AU2016228307A1 (en) 2016-10-06
JP2016117767A (ja) 2016-06-30
CA2830788A1 (en) 2012-09-27
JP2018197276A (ja) 2018-12-13
PT3272342T (pt) 2021-07-12
AU2018202002A1 (en) 2018-04-12
SG10201901167SA (en) 2019-03-28
CN110151731A (zh) 2019-08-23
MX2022013590A (es) 2022-11-16
SG193587A1 (en) 2013-10-30
KR20140030158A (ko) 2014-03-11
EP4011364A1 (en) 2022-06-15
US9028868B2 (en) 2015-05-12
DK4011364T3 (da) 2024-03-18
EP4316488A2 (en) 2024-02-07
ES2644942T3 (es) 2017-12-01
JP6043785B2 (ja) 2016-12-14
KR101834033B1 (ko) 2018-04-13
AU2012230733B2 (en) 2016-10-20
BR112013024401A2 (pt) 2017-11-07
EP2688557A1 (en) 2014-01-29
EP2688557B1 (en) 2017-08-23
CA2830788C (en) 2016-05-17
EP3272342A1 (en) 2018-01-24
EP2688557A4 (en) 2014-09-24
DK2688557T3 (da) 2017-11-27
US20120276017A1 (en) 2012-11-01
EP4011364B1 (en) 2023-12-13
CN103608004A (zh) 2014-02-26
JP2020079322A (ja) 2020-05-28
AU2018202002B2 (en) 2019-04-04
ZA201307649B (en) 2014-06-25
WO2012129551A1 (en) 2012-09-27
EP3272342B1 (en) 2021-05-26
BR112013024401B1 (pt) 2022-01-11
PT2688557T (pt) 2017-11-23
JP2017128614A (ja) 2017-07-27
JP2024019726A (ja) 2024-02-09
EP4316488A3 (en) 2024-02-28
MX357551B (es) 2018-07-13
KR20160135373A (ko) 2016-11-25
JP6325148B2 (ja) 2018-05-16
ES2883589T3 (es) 2021-12-09
JP2022066315A (ja) 2022-04-28
MX2013010920A (es) 2014-08-29
MX2021000431A (es) 2022-10-28
AU2012230733A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
DK3272342T3 (da) Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse
DK2890780T3 (da) Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand
DK2812452T3 (da) Fremgangsmåder og sammensætninger til screening og behandling af udviklingsforstyrrelser
DK2709613T4 (da) Fremgangsmåder til behandling af hcv
DK2838917T3 (da) Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
DK2776567T3 (da) Sammensætninger og fremgangsmåder til behandling af cytomegalovirus.
DK2768321T3 (da) Fremgangsmåder og sammensætninger til induktion af mæthed
DK2766483T3 (da) Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser
DK2914741T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til forbedring af PCR-specificitet
DK2739293T3 (da) Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK3421051T3 (da) Fremgangsmåder til glycokonjugering og sammensætninger
DK3363901T3 (da) Sammensætninger og fremgangsmåder til præcis identificering af mutationer
DK2699553T3 (da) Substituerede diaminocarboxamid- og diaminocarbonitrilpyrimidiner, sammensætninger deraf og fremgangsmåder til behandling dermed
DK2941258T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer ved anvendelse af bakterier
DK2830654T3 (da) Metoder og sammensætninger til behandling af inflammation
BR112014010450A2 (pt) composição e método
DK2680829T3 (da) Sammensætninger og metoder til ikke-kirurgisk behandling af ptosis
DK2854769T3 (da) Fremgangsmåder til behandling af artritis
DK2994533T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK2857019T3 (da) Fremgangsmåde til behandling af multipel sklerose
DK3581199T3 (da) Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis
DK2897611T3 (da) Fremgangsmåder til behandling af hepatitis c
DK2552484T3 (da) Fremgangsmåder og sammensætninger til reducering af parathyroidniveauer
DK2935572T3 (da) Modificerede biokatalysatorer og fremgangsmåder til syntetisering af chirale aminer
DK2704744T3 (da) Komplementfaktor-b-analoger og anvendelser deraf